Safety of adjuvants
The Committee considered the safety of adjuvants used in vaccines. This hitherto neglected subject is becoming increasingly important given modern advances in vaccine development and manufacture. WHO is developing a web site to make available all relevant preclinical and clinical trial information pertaining to the safety of vaccine adjuvants. With the development of vaccines for malaria, human immunodeficiency virus (HIV), human papillomavirus and hepatitis B and of other complex modern vaccines, adjuvant safety has become a central issue. Increasingly in the future there will be a need in developing countries for surveillance of vaccine adjuvant safety following vaccine registration. This applies not only to new vaccines but also to vaccines already available and used for new indications. GACVS will participate in developing such safety surveillance.